Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
ViroMissile, Inc.
Children's Oncology Group
St. Jude Children's Research Hospital
University of Nebraska
National Cancer Institute (NCI)
AccSalus Biosciences, Inc.
Cancer Research UK
Day One Biopharmaceuticals, Inc.
Travera Inc
JS InnoPharm, LLC
University Health Network, Toronto
Purple Biotech Ltd.
Aminex Therapeutics, Inc.
RECORDATI GROUP
Mayo Clinic
Xencor, Inc.
Provectus Pharmaceuticals
Novartis
Infinity Pharmaceuticals, Inc.
SpeciCare
Fore Biotherapeutics
Central Hospital, Nancy, France
Ohio State University Comprehensive Cancer Center
University of California, San Francisco
Virginia Commonwealth University
Merck Sharp & Dohme LLC
INSYS Therapeutics Inc
Delcath Systems Inc.
National Cancer Institute (NCI)
Novartis
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Exelixis
Rutgers, The State University of New Jersey